Skip to Content

Notice

Drug and Biological Product Consolidation; Investigational New Drug Application Number Conversion

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 69772

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing that the Center for Drug Evaluation and Research (CDER) will assign new numbers to a group of investigational new drug applications (INDs). In 2003, FDA transferred certain product oversight responsibilities from the Center for Biologics Evaluation and Research (CBER) to CDER. The consolidation of INDs transferred from CBER with CDER INDs resulted in INDs with duplicate numbers. To resolve this issue, CDER is renumbering some INDs that were submitted to CDER before the consolidation. This Federal Register notice serves to notify sponsors in lieu of sending letters to them.

ADDRESSES:

Information on CDER IND renumbering is available on the Internet at http://www.fda.gov/​cder/​regulatory/​applications/​INDrenumbering.htm.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Samuel Y. Wu, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., bldg. WO22, rm. 1121, Silver Spring, MD 20993, 301-796-0637.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

I. Therapeutic Biological Products Transferred to CDER

On October 1, 2003, FDA transferred responsibility for regulating most therapeutic biologics, with certain exceptions (e.g., cell and gene therapy products and therapeutic vaccines), from the Office of Therapeutics Research and Review, CBER, to the Office of New Drugs, CDER, and the Office of Pharmaceutical Science, CDER (68 FR 38067, June 26, 2003). Applications for the therapeutic biological products now under CDER's review—including INDs, biologics license applications, investigational device exemptions, and new drug applications—were transferred to CDER. For more information on the transfer of therapeutic biological products from CBER to CDER, see FDA's Web site http://www.fda.gov/​cber/​transfer/​transfer.htm.

II. Duplicate IND Numbers

The consolidation of INDs transferred from CBER to CDER has resulted in duplicate IND numbers. To resolve this issue, INDs numbered below 14,000 that were submitted to CDER before the consolidation will be assigned new numbers. To determine the new number, CDER has added 80,000 to the original IND number. For example, IND 8,999 will become IND 88,999 and IND 11,192 will become 91,192. INDs that were originally submitted to CBER and transferred to CDER will retain their numbers.

III. Web Site for Information on Renumbered INDs

FDA has created a Web site with more detailed information about the IND number conversion scheme. The Web site address is http://www.fda.gov/​cder/​regulatory/​applications/​INDrenumbering.htm.

Start Signature

Dated: November 8, 2005.

Jeffrey Shuren,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 05-22802 Filed 11-16-05; 8:45 am]

BILLING CODE 4160-01-S